avelumab

Also known as MSB0010718C, anti-PD-L1 mAb, anti-PD-L1 monoclonal antibody, Immunoglobulin G1-lambda1, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), homo sapiens monoclonal antibody, MSB-0010718C, Bavencio

Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.

Key facts

Drug.type: mab
Drug.mab_type: mab
Drug.source: u
Drug.target: PD-L1
Drug.tradename: Bavencio
Drug.MedlinePlus: a617006
Drug.DailyMedID: Avelumab
Drug.pregnancy_AU: D
Drug.routes_of_administration: Intravenous infusion
Drug.ATC_prefix: L01
Drug.ATC_suffix: FF04
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.metabolism: Proteolysis
Drug.elimination_half life: 6.1 days
Drug.CAS_number: 1537032-82-8

via Wikipedia infobox

Wikidata facts

Show 1 more fact

World Health Organisation international non-proprietary name: avelumab

Sources (4)

via Wikidata · CC0

~7 min read

Article

8 sections

Contents

Medical uses
Contraindications
Side effects
Interactions
Pharmacology
Mechanism of action
History
References

Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.

Common side effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite and swelling of the limbs (peripheral edema).